keyword
MENU ▼
Read by QxMD icon Read
search

Lisdexamfetamine

keyword
https://www.readbyqxmd.com/read/29790103/growth-and-puberty-in-a-2-year-open-label-study-of-lisdexamfetamine-dimesylate-in-children-and-adolescents-with-attention-deficit-hyperactivity-disorder
#1
Tobias Banaschewski, Mats Johnson, Peter Nagy, Isabel Hernández Otero, César A Soutullo, Brian Yan, Alessandro Zuddas, David R Coghill
BACKGROUND: Stimulant medications for the treatment of attention-deficit/hyperactivity disorder have a history of safe and effective use; however, concerns exist that they may adversely affect growth trajectories in children and adolescents. OBJECTIVE: The objective of this study was to evaluate the longer-term effects of lisdexamfetamine dimesylate on weight, height, body mass index and pubertal development in children and adolescents with attention-deficit/hyperactivity disorder...
May 23, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29662527/stimulant-withdrawal-in-a-child-with-autism-spectrum-disorder-and-adhd-a-case-report
#2
Aneta Krakowski, Abel Ickowicz
Objective: To consider whether the concepts of tolerance and withdrawal to stimulant medications apply to a preadolescent female, affected by autism spectrum disorder (ASD) and treated for associated attention-deficit/hyperactivity disorder (ADHD). Methods: We describe the case history and review scientific English language literature pertaining to acute withdrawal effects associated with methylphenidate and amphetamine derivatives in children. Results: An 11-year-old female with ASD and ADHD referred to our clinic experienced vomiting, headaches, and light sensitivity following abrupt discontinuation of methylphenidate; she subsequently presented with migraines and marked malaise immediately after a dose reduction in lisdexamfetamine...
April 2018: Journal of the Canadian Academy of Child and Adolescent Psychiatry
https://www.readbyqxmd.com/read/29661516/lisdexamfetamine-targets-amygdala-mechanisms-that-bias-cognitive-control-in-attention-deficit-hyperactivity-disorder
#3
Kurt P Schulz, Beth Krone, Lenard A Adler, Anne-Claude V Bédard, Stephanie Duhoux, Juan Pedraza, Sanweda Mahagabin, Jeffrey H Newcorn
BACKGROUND: Prefrontal-limbic circuits that form the neural architecture for emotion to influence behavior have been implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD) and represent a potentially important target of medication treatment that has not been substantively evaluated. This study tested the effect of the psychostimulant prodrug lisdexamfetamine dimesylate on amygdala activation and connectivity during the emotional bias of response execution and inhibition...
March 19, 2018: Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
https://www.readbyqxmd.com/read/29511807/acute-effects-of-lisdexamfetamine-and-d-amphetamine-on-social-cognition-and-cognitive-performance-in-a-placebo-controlled-study-in-healthy-subjects
#4
Patrick C Dolder, Petra Strajhar, Patrick Vizeli, Alex Odermatt, Matthias E Liechti
RATIONALE: Amphetamines are used as medications but are also misused as cognitive enhancers by healthy subjects and may have additional effects on social cognition. METHODS: We investigated the acute effects of single, high, equimolar doses of D-amphetamine (40 mg) and lisdexamfetamine (100 mg) on social cognition and cognitive performance using a randomized, placebo-controlled, double-blind, cross-over design in 24 healthy volunteers. Effects on social cognition were assessed using the Facial Emotion Recognition Task (FERT), Multifaceted Empathy Test (MET), and Sexual Arousal Task (SAT)...
May 2018: Psychopharmacology
https://www.readbyqxmd.com/read/29497297/relationships-between-clinical-scales-and-binge-eating-days-in-adults-with-moderate-to-severe-binge-eating-disorder-in-two-phase-iii-studies
#5
Leslie Citrome, Judith C Kando, Caleb Bliss
Objectives: In two Phase III studies, lisdexamfetamine dimesylate (LDX) reduced binge eating (BE) days/week in adults with moderate to severe binge eating disorder (BED) and was associated with improvement based on the Clinical Global Impressions-Improvement (CGI-I) scale. In this study, post hoc analyses examined the relationships between clinical observations and clinical rating scales in individuals with BED. Clinical trial registration: NCT01718483 (ClinicalTrials...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29460165/efficacy-and-safety-of-drugs-for-attention-deficit-hyperactivity-disorder-in-children-and-adolescents-a-network-meta-analysis
#6
Sarah C O S Padilha, Suzane Virtuoso, Fernanda S Tonin, Helena H L Borba, Roberto Pontarolo
The aim of this study is to gather evidence of head-to-head double-blind randomized-controlled trials on the efficacy and safety of available treatments for attention deficit hyperactivity disorder (ADHD) in children and adolescents. A systematic review was conducted by two independent reviewers in ten electronic databases (PROSPERO register CRD42016043239). Methodological quality of included studies was evaluated according to the Jadad scale. Network meta-analyses were performed including double-blinded head-to-head trials comparing active allopathic drugs in patients (0-18 years old) diagnosed with ADHD...
February 19, 2018: European Child & Adolescent Psychiatry
https://www.readbyqxmd.com/read/29406017/examining-the-effectiveness-of-acetylcholinesterase-inhibitors-and-stimulant-based-medications-for-cognitive-dysfunction-in-multiple-sclerosis-a-systematic-review-and-meta-analysis
#7
REVIEW
Jack Cotter, Nils Muhlert, Anahita Talwar, Kiri Granger
We sought to examine the effectiveness of acetylcholinesterase inhibitors (AChEIs) and stimulant-based medications for improving cognitive performance in patients with multiple sclerosis (MS). An electronic database search was conducted on 25th March 2017. Eligible studies were double-blind, randomised, placebo-controlled trials that examined the efficacy of compounds that act primarily as AChEIs or stimulants (administered daily for ≥1 week) on cognitive outcome measures in patients with MS. Where suitable data was reported, we generated effect sizes and corresponding 95% confidence intervals and performed meta-analyses using random-effects models to investigate the effectiveness of these drug types across cognitive domains...
March 2018: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/29383572/cognitive-function-of-children-and-adolescents-with-attention-deficit-hyperactivity-disorder-in-a-2-year-open-label-study-of-lisdexamfetamine-dimesylate
#8
David R Coghill, Tobias Banaschewski, Caleb Bliss, Brigitte Robertson, Alessandro Zuddas
BACKGROUND: SPD489-404 was the first 2-year safety study of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. In accordance with advice from the European Medicines Agency, assessment of cognitive function was a predefined safety outcome in SPD489-404. OBJECTIVE: The objective of this study was to assess cognitive function over 2 years in study SPD489-404, using the Cambridge Neuropsychological Test Automated Battery (CANTAB)...
January 2018: CNS Drugs
https://www.readbyqxmd.com/read/29346342/attention-deficit-hyperactivity-disorder-medication-prescription-claims-among-privately-insured-women-aged-15-44-years-united-states-2003-2015
#9
Kayla N Anderson, Elizabeth C Ailes, Melissa Danielson, Jennifer N Lind, Sherry L Farr, Cheryl S Broussard, Sarah C Tinker
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that affects individuals across the lifespan. ADHD medication use among pregnant women is increasing (1), but consensus about the safety of ADHD medication use during pregnancy is lacking. Given that nearly half of U.S. pregnancies are unintended (2), and early pregnancy is a critical period for fetal development, examining trends in ADHD medication prescriptions among reproductive-aged women is important to quantify the population at risk for potential exposure...
January 19, 2018: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/29258368/lisdexamfetamine-chemistry-pharmacodynamics-pharmacokinetics-and-clinical-efficacy-safety-and-tolerability-in-the-treatment-of-binge-eating-disorder
#10
REVIEW
Kristen Ward, Leslie Citrome
The indications for lisdexamfetamine (LDX), a central nervous system stimulant, were recently expanded to include treatment of moderate to severe binge eating disorder (BED). Areas covered: This review aims to describe the chemistry and pharmacology of LDX, as well as the clinical trials investigating the efficacy and safety of this medication for the management of BED. Expert opinion: LDX is the first medication with United States Food and Drug Administration approval for the treatment of BED. It is an inactive prodrug of d-amphetamine that extends the half-life of d-amphetamine to allow for once daily dosing...
February 2018: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29186993/medication-use-in-adults-with-attention-deficit-hyperactivity-disorder-in-a-commercially-insured-population-in-the-united-states
#11
Zhou Zhou, Zheng-Yi Zhou, Sneha S Kelkar, Vanja Sikirica, Jipan Xie, Regina Grebla
OBJECTIVE: To examine real-world prescription medication usage among commercially-insured adults with attention deficit/hyperactivity disorder (ADHD) in the US. METHODS: Adults with ADHD who received ≥1 ADHD medication during 2013 were identified from a large US claims database. Combination therapy was defined as an overlap of ≥30 days between the index (first treatment ≥30 days in 2013) and another medication(s). Patients were classified into six groups: long-acting (LA) monotherapy, short-acting (SA) monotherapy, LA + LA, SA + SA, LA + SA, and >2 therapies...
April 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29180967/efficacy-and-tolerability-of-different-interventions-in-children-and-adolescents-with-attention-deficit-hyperactivity-disorder
#12
Ruiling Luan, Zhiling Mu, Fang Yue, Shaoying He
Background: Our study is an analysis of multiple publications involving assessing the comparable efficacy and tolerability of six interventions, which are lisdexamfetamine dimesylate (LDX), atomoxetine (ATX), methylphenidate (MPH), clonidine hydrochloride (CLON), guanfacine extended release (GXR), and bupropion, for young patients (6-18 years old) suffering from attention deficit hyperactivity disorder (ADHD). Methods: A conventional meta-analysis (MA) was performed to give direct comparisons and a network meta-analysis (NMA) was used to show the combination of direct and indirect evidence...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29134566/lisdexamfetamine-a-review-in-binge-eating-disorder
#13
Young-A Heo, Sean T Duggan
Oral lisdexamfetamine dimesylate (Vyvanse® ; lisdexamfetamine), a prodrug of dextroamfetamine, is currently the only drug to be approved in the USA for the treatment of moderate to severe binge eating disorder (BED) in adult patients. Its approval was based on the results of two pivotal short-term (12 weeks) phase III studies, which showed a significantly greater reduction in binge eating days/week at the end of the study with lisdexamfetamine 50-70 mg/day than with placebo. The findings of these studies have been supported and extended by the results of longer-term (≤ 52 weeks) phase III studies, including one with a randomized 26-week withdrawal phase, which showed that lisdexamfetamine markedly reduced the risk of BED relapse relative to placebo...
November 2017: CNS Drugs
https://www.readbyqxmd.com/read/29113456/a-systematic-review-of-cost-effectiveness-studies-of-prevention-and-treatment-for-eating-disorders
#14
Long Khanh-Dao Le, Phillipa Hay, Cathrine Mihalopoulos
BACKGROUND: Eating disorders are serious mental disorders and are associated with substantial economic and social burden. The aim of this study is to undertake a systematic review of the cost-effectiveness studies of both preventive and treatment interventions for eating disorder. METHOD: Electronic databases (including the Cochrane Controlled Trial Register, MEDLINE, PsycINFO, Academic Search Complete, Global Health, CINAHL complete, Health Business Elite, Econlit, Health Policy Reference Center and ERIC) were searched for published cost-effectiveness studies of eating disorder prevention and treatment including papers published up to January 2017...
April 2018: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/29053927/safety-of-pharmacotherapy-options-for-bulimia-nervosa-and-binge-eating-disorder
#15
Nicholas T Bello, Bryn L Yeomans
Eating disorders represent a set of psychiatric illnesses with lifelong complications and high relapse rates. Individuals with eating disorders are often stigmatized and clinicians have a limited set of treatments options. Pharmacotherapy has the potential to improve long term compliance and patient commitment to treatment for eating disorders. Areas Covered: This review will examine the efficacy and safety profile of the FDA-approved medications for the treatment of bulimia nervosa (BN) and binge eating disorder (BED)...
October 20, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29044551/disordered-eating-and-obesity-associations-between-binge-eating-disorder-night-eating-syndrome-and-weight-related-comorbidities
#16
REVIEW
Courtney McCuen-Wurst, Madelyn Ruggieri, Kelly C Allison
Binge-eating disorder (BED) and night-eating syndrome (NES) are two forms of disordered eating associated with overweight and obesity. While these disorders also occur in nonobese persons, they seem to be associated with weight gain over time and higher risk of diabetes and other metabolic dysfunction. BED and NES are also associated with higher risk of psychopathology, including mood, anxiety, and sleep problems, than those of similar weight status without disordered eating. Treatments are available, including cognitive behavior therapy (CBT), interpersonal psychotherapy, lisdexamfetamine, and selective serotonin reuptake inhibitors (SSRIs) for BED; and CBT, SSRIs, progressive muscle relaxation, and bright light therapy for NES...
January 2018: Annals of the New York Academy of Sciences
https://www.readbyqxmd.com/read/29028590/efficacy-and-tolerability-of-lisdexamfetamine-as-an-antidepressant-augmentation-strategy-a-meta-analysis-of-randomized-controlled-trials
#17
Peter Giacobbe, Uros Rakita, Raymond Lam, Roumen Milev, Sidney H Kennedy, Roger S McIntyre
BACKGROUND: Psychostimulants have been used in the treatment of depression, with mixed results. This meta-analysis examines the efficacy and tolerability of the stimulant Lisdexamfetamine (LDX) as an add-on strategy in those with MDD who have failed to respond to an antidepressant. METHOD: Randomized control trials were identified and extracted from Pubmed; Web of Science; PsychINFO; and Cochrane Library. The efficacy of LDX was evaluated using Hedges' g and Odds Ratio, whereas Risk Difference was used to assess the safety and tolerability of LDX...
January 15, 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28980198/randomized-double-blind-placebo-controlled-acute-comparator-trials-of-lisdexamfetamine-and-extended-release-methylphenidate-in-adolescents-with-attention-deficit-hyperactivity-disorder
#18
Jeffrey H Newcorn, Peter Nagy, Ann C Childress, Glen Frick, Brian Yan, Steven Pliszka
BACKGROUND: Psychostimulants are considered first-line pharmacotherapy for youth with attention-deficit/hyperactivity disorder (ADHD), but questions remain regarding the comparative efficacy of amphetamine- and methylphenidate-based agents. OBJECTIVE: Our objective was to describe two acute randomized, double-blind, placebo-controlled, head-to-head studies of lisdexamfetamine dimesylate (LDX) and osmotic-release oral system methylphenidate (OROS-MPH) in adolescents with ADHD...
November 2017: CNS Drugs
https://www.readbyqxmd.com/read/28936175/pharmacokinetics-and-pharmacodynamics-of-lisdexamfetamine-compared-with-d-amphetamine-in-healthy-subjects
#19
Patrick C Dolder, Petra Strajhar, Patrick Vizeli, Felix Hammann, Alex Odermatt, Matthias E Liechti
Rationale: Lisdexamfetamine is a prodrug of D-amphetamine used for the treatment of attention-deficit/hyperactivity disorder (ADHD). Lisdexamfetamine is thought to have a prolonged pharmacokinetic profile compared with oral D-amphetamine, possibly associated with lower drug liking and a lower risk of oral misuse. However, differences in the pharmacokinetics and pharmacodynamics of lisdexamfetamine and D-amphetamine have not been directly compared. Methods: Equimolar doses of D-amphetamine (40 mg) and lisdexamfetamine (100 mg), and placebo were administered in 24 healthy subjects in a randomized, double-blind, placebo-controlled, cross-over study...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28933969/psychopharmacological-advances-in-eating-disorders
#20
REVIEW
Hubertus Himmerich, Janet Treasure
Anorexia nervosa (AN), bulimia nervosa (BN) and binge eating disorder (BED) are the primary eating disorders (EDs). The only psychopharmacological treatment options for EDs with approval in some countries include fluoxetine for BN and lisdexamfetamine for BED. Given the high comorbidity and genetic correlations with other psychiatric disorders, it seems possible that novel medications for these conditions might also be effective in EDs. Areas covered: The current scientific literature has increased our understanding of how medication could be beneficial for patients with EDs on a molecular, functional and behavioral level...
January 2018: Expert Review of Clinical Pharmacology
keyword
keyword
7577
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"